# Cetuximab Rechallenge Study

> **NCT01832467** · PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** cetuximab-containing chemotherapy

## Key facts

- **NCT ID:** NCT01832467
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-24
- **Primary completion:** 2020-04-07
- **Final completion:** 2020-04-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832467, "Cetuximab Rechallenge Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01832467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*